Fifty-nine patients completed 12 months of follow-up, 1 patient was lost to follow-up, and 4 patients withdrew from the study. No serious treatment-related AEs were reported. Minor events related to biopsy included hematoma (2/64) and bleeding requiring sutures (1/64). Genitourinary events within 30 days of AMDC injection were limited to dysuria (3/64), pelvic/abdominal pain or cramping (3/64), vaginal and/or urethral itching (3/64), transient hematuria (2/64), increased frequency/urgency (1/64), and transient sensation

of a foreign object in the urethra (1/64). Patients with moderate to severe SUI (ie, ≥ 3 stress leaks over 3 days and ≥ 3 g increase in pad weight at baseline) were included in the

Inhibitors,research,lifescience,medical effectiveness analysis. The percentage of patients who experienced ≥ 50% reduction in baseline stress leaks and pad weight increased with increasing dose is shown in Table 7. Out of the four different dose groups, 200 × 106 dose Inhibitors,research,lifescience,medical group at 12 months showed that 100% (6/6) of patients had ≥ 50% reduction in stress leaks and 83% (5/6) had ≥ 50% reduction in pad weight. Additionally, the 200 × 106 group had the highest percentage of patients with 0 to 1 leaks (83%, 5/6), Stamey scores of 0 (50%, 3/6), and ≥ 50% improvement in quality of life scores (83%, Inhibitors,research,lifescience,medical 5/6 for IIQ-7; 67%, 4/6 for UDI-6). The study’s conclusions were that intrasphincter injection of AMDC at doses of 10, 50, 100, and 200 × 106 cells is safe. AMDC treatment may improve symptoms and quality of life in women with SUI and more patients may be responsive to higher Inhibitors,research,lifescience,medical doses of AMDC. A double-blind, randomized, placebo-controlled, confirmatory study of AMDC treatment for female SUI is currently underway (ClinicalTrials. gov Identifier: NCT01382602).9 Table 7 Percentage of Patients Meeting Each Endpoint at 12 Monthsa [Jayabalan Nirmal, PhD, Michael B. Chancellor, MD] Prostate Cancer Screening Prostate cancer screening was a major focus at the 2012 AUA Annual Meeting. At the plenary session, updated results

from the European Randomized Study of Screening Inhibitors,research,lifescience,medical for Prostate Cancer (ERSPC) were presented. This is the largest randomized study of prostate-specific antigen (PSA) screening and, at 11-year follow-up, they found that it reduced metastatic disease and led to a 21% reduction in prostate cancer-specific almost mortality.10 That notwithstanding, the United States EGFR inhibitor review Preventive Services Task Force (USPSTF) issued a Grade D recommendation against PSA screening on May 21, 2012.11 The AUA issued a response stating that “the USPSTF, in disparaging the PSA test before a newer diagnostic is more readily available, does a great disservice to American men and may cause more harm than good. It is inappropriate and irresponsible to issue a blanket statement against PSA testing, particularly for at-risk populations such as black men and those with a family history of the disease.